US5332744A
(en)
*
|
1989-05-30 |
1994-07-26 |
Merck & Co., Inc. |
Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
|
US5223499A
(en)
*
|
1989-05-30 |
1993-06-29 |
Merck & Co., Inc. |
6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists
|
IE70593B1
(en)
*
|
1989-09-29 |
1996-12-11 |
Eisai Co Ltd |
Biphenylmethane derivative the use of it and pharmacological compositions containing same
|
US5196444A
(en)
*
|
1990-04-27 |
1993-03-23 |
Takeda Chemical Industries, Ltd. |
1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
|
DE4036706A1
(de)
*
|
1990-11-17 |
1992-05-21 |
Hoechst Ag |
Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie
|
GB9027208D0
(en)
*
|
1990-12-14 |
1991-02-06 |
Smithkline Beecham Plc |
Medicaments
|
GB9027198D0
(en)
*
|
1990-12-14 |
1991-02-06 |
Smithkline Beecham Plc |
Medicaments
|
SI9210098B
(sl)
*
|
1991-02-06 |
2000-06-30 |
Dr. Karl Thomae |
Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
|
FR2673427B1
(fr)
*
|
1991-03-01 |
1993-06-18 |
Sanofi Elf |
Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
|
TW274551B
(fi)
*
|
1991-04-16 |
1996-04-21 |
Takeda Pharm Industry Co Ltd |
|
IL102183A
(en)
*
|
1991-06-27 |
1999-11-30 |
Takeda Chemical Industries Ltd |
The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
|
US5354759A
(en)
*
|
1991-09-12 |
1994-10-11 |
Fujisawa Pharmaceutical Co., Ltd. |
Angiotenin II antagonizing heterocyclic compounds
|
GB9201789D0
(en)
*
|
1992-01-28 |
1992-03-11 |
Fujisawa Pharmaceutical Co |
Heterocyclic derivatives
|
TW284688B
(fi)
*
|
1991-11-20 |
1996-09-01 |
Takeda Pharm Industry Co Ltd |
|
JP2682353B2
(ja)
*
|
1991-11-20 |
1997-11-26 |
武田薬品工業株式会社 |
経口用医薬組成物およびその製造法
|
DE4203872A1
(de)
*
|
1992-02-11 |
1993-08-12 |
Thomae Gmbh Dr K |
Imidazo(1,2-a)pyridine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
|
WO1993018030A1
(en)
*
|
1992-03-03 |
1993-09-16 |
Fujisawa Pharmaceutical Co., Ltd. |
Benzimidazole derivatives as angiotensin ii antagonists
|
US5310929A
(en)
*
|
1992-08-06 |
1994-05-10 |
E. I. Du Pont De Nemours And Company |
Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
|
US5266583A
(en)
*
|
1992-09-01 |
1993-11-30 |
Merck & Co., Inc. |
Angitotensin II antagonist
|
DK154092D0
(da)
*
|
1992-12-23 |
1992-12-23 |
Neurosearch As |
Imidazolforbindelser, deres fremstilling og anvendelse
|
CA2115985A1
(en)
*
|
1993-02-25 |
1994-08-26 |
Kohei Nishikawa |
Vascular hypertrophy suppressor
|
JP2787539B2
(ja)
*
|
1993-02-26 |
1998-08-20 |
松森 昭 |
ウイルス性疾患の予防または治療剤
|
JP3810020B2
(ja)
|
1993-04-22 |
2006-08-16 |
武田薬品工業株式会社 |
腎疾患の予防または治療剤
|
JP2003306432A
(ja)
*
|
1993-04-22 |
2003-10-28 |
Takeda Chem Ind Ltd |
腎疾患の予防または治療剤
|
US5721263A
(en)
|
1993-06-07 |
1998-02-24 |
Takeda Chemical Industries, Ltd. |
Pharmaceutical composition for angiotensin II-mediated diseases
|
JP3057471B2
(ja)
*
|
1993-06-07 |
2000-06-26 |
武田薬品工業株式会社 |
アンジオテンシンii介在性諸疾患の予防または治療剤
|
CA2125251C
(en)
*
|
1993-06-07 |
2005-04-26 |
Yoshiyuki Inada |
A pharmaceutical composition for angiotensin ii-mediated diseases
|
CZ154994A3
(en)
*
|
1993-07-02 |
1995-09-13 |
Senju Pharma Co |
Visual hypotensive agent
|
US5391566A
(en)
*
|
1993-07-20 |
1995-02-21 |
Merck & Co., Inc. |
Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives
|
ZA945190B
(en)
*
|
1993-07-30 |
1995-02-24 |
Kotobuki Seiyaku Co Ltd |
Carboxymethylidenecycloheptimidazole derivatives method or manufacturing the same and therapeutic agents containing these compounds
|
US5824696A
(en)
*
|
1993-09-01 |
1998-10-20 |
Smithkline Beecham Corporation |
Medicaments
|
US6676967B1
(en)
*
|
1993-09-20 |
2004-01-13 |
Kos Pharmaceuticals, Inc. |
Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
|
ES2147798T3
(es)
*
|
1994-01-28 |
2000-10-01 |
Takeda Chemical Industries Ltd |
Un procedimiento para la produccion de compuestos de tetrazolilo.
|
DE4408497A1
(de)
*
|
1994-03-14 |
1995-09-21 |
Thomae Gmbh Dr K |
Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
|
EP1110551B1
(en)
*
|
1994-03-16 |
2004-05-12 |
Sankyo Company Limited |
Ocular tension lowering agent
|
AU677702B2
(en)
*
|
1994-10-13 |
1997-05-01 |
Takeda Pharmaceutical Company Limited |
A prophylactic or therapeutic drug for renal diseases
|
SE9501881D0
(sv)
*
|
1995-05-19 |
1995-05-19 |
Astra Ab |
New pharmacological use of AII-receptor antagonists
|
SE9502219D0
(sv)
*
|
1995-06-19 |
1995-06-19 |
Astra Ab |
Novel medical use
|
DE69624253T2
(de)
*
|
1995-10-06 |
2003-08-07 |
Novartis Ag, Basel |
Ati-rezeptorantagonisten zur verhinderung und behandlung des postischemischen nervenversagens und zum schutze ischemischer nieren
|
HUP9900625A3
(en)
|
1995-12-28 |
2003-04-28 |
Fujisawa Pharmaceutical Co |
Benzimidazole derivatives, pharmaceutical compositions containing them and process for preparing the compounds
|
AU1791497A
(en)
|
1996-02-29 |
1997-09-16 |
Novartis Ag |
At1 receptor antagonist for the stimulation of apoptosis
|
RU2188013C2
(ru)
*
|
1996-04-05 |
2002-08-27 |
Такеда Кемикал Индастриз, Лтд. |
Комбинация, содержащая соединение, имеющее ангиотензин ii антагонистическую активность
|
US5771604A
(en)
*
|
1997-04-07 |
1998-06-30 |
Maytag Corporation |
Clothes dryer air inlet arrangement
|
US6177587B1
(en)
|
1997-05-26 |
2001-01-23 |
Takeda Chemical Industries, Ltd. |
Production method of aminobenzene compound
|
TW453999B
(en)
|
1997-06-27 |
2001-09-11 |
Fujisawa Pharmaceutical Co |
Benzimidazole derivatives
|
ES2238770T5
(es)
|
1997-10-17 |
2012-01-17 |
Ark Therapeutics Limited |
Utilización de inhibidores del sistema renina-angiotensina para el tratamiento de la hipoxia o de la disminución de la función metabólica.
|
EP1069113A1
(en)
|
1998-02-23 |
2001-01-17 |
Kureha Chemical Industry Co., Ltd. |
Benzimidazole derivative
|
DE19820151A1
(de)
*
|
1998-05-06 |
1999-11-11 |
Hexal Ag |
Transdermales therapeutisches System zur Anwendung von Candesartan
|
US6638937B2
(en)
|
1998-07-06 |
2003-10-28 |
Bristol-Myers Squibb Co. |
Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
|
TR200100047T2
(tr)
|
1998-07-15 |
2001-10-22 |
Teijin Limited |
Tiyobenzimidazol türevleri
|
US6465502B1
(en)
|
1998-12-23 |
2002-10-15 |
Novartis Ag |
Additional therapeutic use
|
TR200605472T1
(tr)
|
1998-12-23 |
2007-02-21 |
Novartis Ag |
AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@
|
CN101011390A
(zh)
|
1999-01-26 |
2007-08-08 |
诺瓦提斯公司 |
血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
|
GB0001662D0
(en)
*
|
1999-02-06 |
2000-03-15 |
Zeneca Ltd |
Pharmaceutical compositions
|
US7378108B1
(en)
|
1999-02-19 |
2008-05-27 |
Takeda Pharmaceutical Company Limited |
Percutaneous absorption preparation of compound having angiotensin II antagonistic activity
|
US6211217B1
(en)
|
1999-03-16 |
2001-04-03 |
Novartis Ag |
Method for reducing pericardial fibrosis and adhesion formation
|
EE200100673A
(et)
*
|
1999-06-10 |
2003-02-17 |
Warner-Lambert Company |
Meetod amüloidvalgu agregatsiooni inhibeerimiseksja amüloiddeposiitide piltdiagnostika läbiviimiseks
|
US6972287B1
(en)
|
1999-06-10 |
2005-12-06 |
Pfizer Inc. |
Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
|
EP1867342A1
(en)
*
|
1999-07-21 |
2007-12-19 |
Takeda Pharmaceutical Company Limited |
Agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof
|
SE9903028D0
(sv)
|
1999-08-27 |
1999-08-27 |
Astra Ab |
New use
|
RS50377B
(sr)
*
|
1999-08-30 |
2009-11-10 |
Sanofi-Aventis Deutschland Gmbh., |
Inhibitori sistema renin-angiotenzin i njihova primena
|
WO2001060362A1
(en)
*
|
2000-02-18 |
2001-08-23 |
Takeda Chemical Industries, Ltd. |
TNF-α INHIBITORS
|
SE0002353D0
(sv)
*
|
2000-06-22 |
2000-06-22 |
Astrazeneca Ab |
New use
|
CA2417635C
(en)
*
|
2000-08-11 |
2008-02-05 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Heterocyclic compounds useful as inhibitors of tyrosine kinases
|
PE20020617A1
(es)
|
2000-08-22 |
2002-08-05 |
Novartis Ag |
Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
|
WO2002017913A1
(fr)
*
|
2000-08-30 |
2002-03-07 |
Sankyo Company, Limited |
Compositions medicinales utilisees dans la prevention ou le traitement de l'insuffisance cardiaque
|
EP1329218A4
(en)
*
|
2000-10-25 |
2007-04-04 |
Takeda Pharmaceutical |
AGENTS FOR PREVENTIVE AND TREATING PORTAL HYPERTENSION
|
US8168616B1
(en)
|
2000-11-17 |
2012-05-01 |
Novartis Ag |
Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
|
US7090869B2
(en)
|
2000-12-01 |
2006-08-15 |
Takeda Pharmaceutical Company Limited |
Method for producing preparation containing bioactive substance
|
WO2003014112A1
(fr)
*
|
2001-08-03 |
2003-02-20 |
Takeda Chemical Industries, Ltd. |
Cristal et procede de fabrication correspondant
|
EP1421953A4
(en)
*
|
2001-08-28 |
2004-09-15 |
Sankyo Co |
MEDICINAL COMPOSITIONS CONTAINING AN ANGIOTENSIN II RECEPTOR ANTAGONIST
|
US7107198B2
(en)
*
|
2001-11-02 |
2006-09-12 |
Sun Microsystems, Inc. |
Automatic generation of reduced-size circuit models including inductive interaction
|
CA2466659A1
(en)
|
2001-11-13 |
2003-05-22 |
Takeda Chemical Industries, Ltd. |
Anticancer agents
|
DE10205335A1
(de)
*
|
2002-02-07 |
2003-08-21 |
Bdd Group Holding Ag Zug |
Deuterierte biphenylsubstituierte Benzimidazole sowie diese Verbindungen enthaltende Arzneimittel
|
AU2003218056A1
(en)
*
|
2002-03-01 |
2003-09-16 |
Merck & Co., Inc. |
Aminoalkylphosphonates and related compounds as edg receptor agonists
|
US7232828B2
(en)
*
|
2002-08-10 |
2007-06-19 |
Bethesda Pharmaceuticals, Inc. |
PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
|
AU2003250483A1
(en)
|
2002-08-19 |
2004-03-11 |
Pfizer Products Inc. |
Combination therapy for hyperproliferative diseases
|
DE10335027A1
(de)
|
2003-07-31 |
2005-02-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verwendung von Angiotensin II Rezeptor Antagonisten
|
EP1511739B1
(en)
*
|
2003-03-17 |
2008-04-30 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of valsartan
|
AU2003230193A1
(en)
*
|
2003-03-27 |
2004-10-18 |
Hetero Drugs Limited |
Novel crystalline forms of candesartan cilexetil
|
SE0300988D0
(sv)
*
|
2003-04-03 |
2003-04-03 |
Astrazeneca Ab |
New use
|
WO2004094391A2
(en)
*
|
2003-04-21 |
2004-11-04 |
Teva Pharmaceutical Industries Ltd. |
Process for the preparation of valsartan and intermediates thereof
|
US7732162B2
(en)
|
2003-05-05 |
2010-06-08 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
|
GB0316546D0
(en)
*
|
2003-07-15 |
2003-08-20 |
Novartis Ag |
Process for the manufacture of organic compounds
|
US20050037063A1
(en)
*
|
2003-07-21 |
2005-02-17 |
Bolton Anthony E. |
Combined therapies
|
PL1658281T3
(pl)
*
|
2003-08-27 |
2010-12-31 |
Zentiva Ks |
Sposób usuwania trifenylometanowej grupy zabezpieczającej
|
WO2005030202A1
(en)
*
|
2003-09-26 |
2005-04-07 |
Novartis Ag |
Use of angiotensin ii receptor antagonists for treating cerebrovascular disorders
|
GB0322552D0
(en)
*
|
2003-09-26 |
2003-10-29 |
Astrazeneca Uk Ltd |
Therapeutic treatment
|
DE602004005488T2
(de)
*
|
2003-10-16 |
2007-11-29 |
Teva Pharmaceutical Industries Ltd. |
Verfahren zur herstellung von candesartan cilexetil
|
US20070292498A1
(en)
*
|
2003-11-05 |
2007-12-20 |
Warren Hall |
Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
|
EP2428516A1
(en)
|
2003-11-19 |
2012-03-14 |
Metabasis Therapeutics, Inc. |
Novel phosphorus-containing thyromimetics
|
WO2005051928A1
(en)
*
|
2003-11-28 |
2005-06-09 |
Ranbaxy Laboratories Limited |
Process for production of tetrazolyl compounds
|
GB0327839D0
(en)
|
2003-12-01 |
2003-12-31 |
Novartis Ag |
Organic compounds
|
JP2005206603A
(ja)
*
|
2004-01-21 |
2005-08-04 |
Teva Pharmaceutical Industries Ltd |
カンデサルタンシレキセチルの調製
|
GB0402262D0
(en)
|
2004-02-02 |
2004-03-10 |
Novartis Ag |
Process for the manufacture of organic compounds
|
EP1713795A2
(en)
*
|
2004-02-11 |
2006-10-25 |
Teva Pharmaceutical Industries Ltd. |
Candesartan cilexetil polymorphs
|
US7157584B2
(en)
*
|
2004-02-25 |
2007-01-02 |
Takeda Pharmaceutical Company Limited |
Benzimidazole derivative and use thereof
|
CA2558020A1
(en)
|
2004-03-17 |
2005-09-29 |
Novartis Ag |
Use of renin inhibitors in therapy
|
JP2007532677A
(ja)
*
|
2004-04-16 |
2007-11-15 |
サンタラス インコーポレイティッド |
プロトンポンプ阻害剤、緩衝剤、および運動促進薬の組み合わせ
|
MXPA06012702A
(es)
*
|
2004-05-05 |
2007-04-02 |
Teva Pharma |
Preparacion de candesartan cilexetil de alta pureza.
|
JP2009185060A
(ja)
*
|
2004-05-19 |
2009-08-20 |
Teva Pharmaceutical Industries Ltd |
カンデサルタンシレキセチル多形体
|
JP2005330277A
(ja)
*
|
2004-05-19 |
2005-12-02 |
Teva Pharmaceutical Industries Ltd |
カンデサルタンシレキセチル多形体
|
WO2005117591A2
(en)
*
|
2004-05-28 |
2005-12-15 |
Andrx Labs Llc |
Novel pharmaceutical formulation containing a biguanide and an angiotensin antagonist
|
WO2005123720A1
(en)
*
|
2004-06-18 |
2005-12-29 |
Ranbaxy Laboratories Limited |
Fine particles of the angiotensin ii antagonist candesartan cilexetil and process for production thereof
|
AU2005277138A1
(en)
|
2004-08-23 |
2006-03-02 |
Wyeth Holdings Corporation |
Oxazolo-naphthyl acids as plaminogen activator inhibtor type-1 (PAI-1) modulators useful in the treatment of thrombosis and cardiovascular diseases
|
MX2007002177A
(es)
|
2004-08-23 |
2007-04-02 |
Wyeth Corp |
Acidos de pirrolo-naftilo como inhibidores de pai-1.
|
AU2005277139A1
(en)
|
2004-08-23 |
2006-03-02 |
Wyeth |
Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1
|
AU2005294318A1
(en)
|
2004-10-08 |
2006-04-20 |
Novartis Ag |
Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
|
WO2006046593A1
(ja)
|
2004-10-27 |
2006-05-04 |
Daiichi Sankyo Company, Limited |
2以上の置換基を有するベンゼン化合物
|
JPWO2006046528A1
(ja)
*
|
2004-10-29 |
2008-05-22 |
興和株式会社 |
糸球体疾患治療剤
|
EP1655298A1
(en)
*
|
2004-11-03 |
2006-05-10 |
LEK Pharmaceuticals d.d. |
Novel polymorph forms of candesartan cilexetil
|
EP1812423A1
(en)
|
2004-11-11 |
2007-08-01 |
LEK Pharmaceuticals D.D. |
Process for the synthesis of tetrazoles
|
CA2590533C
(en)
*
|
2004-11-23 |
2010-09-07 |
Warner-Lambert Company Llc |
7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
|
DE102004060699A1
(de)
*
|
2004-12-16 |
2006-06-22 |
Ratiopharm Gmbh |
Verfahren zur Herstellung von Candesartan
|
PT1833801E
(pt)
*
|
2004-12-22 |
2008-08-25 |
Algry Quimica S L |
Compostos intermediários para a preparação de antagonistas do receptor da angiotensina ii
|
WO2006074218A2
(en)
*
|
2005-01-06 |
2006-07-13 |
Elan Pharma International Ltd. |
Nanoparticulate candesartan formulations
|
KR20070088783A
(ko)
*
|
2005-01-14 |
2007-08-29 |
테바 파마슈티컬 인더스트리즈 리미티드 |
조 칸데사르탄 실렉세틸의 제조
|
JP2008528456A
(ja)
*
|
2005-01-26 |
2008-07-31 |
レツク・フアーマシユーテイカルズ・デー・デー |
親油性結晶性物質としてカンデサルタンシレキセチルを含む新規な医薬組成物
|
DE602006017183D1
(de)
*
|
2005-03-30 |
2010-11-11 |
Takeda Pharmaceutical |
Benzimidazolderivat und anwendung davon
|
TW200719896A
(en)
*
|
2005-04-18 |
2007-06-01 |
Astrazeneca Ab |
Combination product
|
CN100400536C
(zh)
*
|
2005-04-30 |
2008-07-09 |
重庆圣华曦药业有限公司 |
坎地沙坦酯c-型晶体的制备方法
|
WO2006122254A2
(en)
*
|
2005-05-10 |
2006-11-16 |
Teva Pharmaceutical Industries Ltd. |
Stable micronized candesartan cilexetil and methods for preparing thereof
|
WO2007074399A2
(en)
|
2005-06-06 |
2007-07-05 |
Medichem, S.A. |
Process for the preparation of tetrazolyl compounds
|
ES2264641B1
(es)
*
|
2005-06-17 |
2008-03-01 |
Quimica Sintetica, S.A. |
Procedimiento para la obtencion de derivados de bencimidazol y sus intermedios.
|
JP2009501184A
(ja)
|
2005-07-13 |
2009-01-15 |
エフ.ホフマン−ラ ロシュ アーゲー |
5−ht6、5−ht24としてのベンゾイミダゾール誘導体
|
SI22127A
(sl)
*
|
2005-10-07 |
2007-04-30 |
Krka, Tovarna Zdravil, D.D., Novo Mesto |
Postopek za pripravo kandesartan cileksetila
|
CZ299265B6
(cs)
*
|
2005-10-20 |
2008-05-28 |
Zentiva, A. S. |
Zpusob výroby 1-(cyklohexyloxykarbonyloxy)ethyl-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)bifenyl-4-yl]methyl]benzimidazol-7-karboxylátu (candesartan cilexetilu)
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
CN100344625C
(zh)
*
|
2005-12-22 |
2007-10-24 |
浙江天宇药业有限公司 |
一种制备坎地沙坦的方法
|
WO2007094015A1
(en)
*
|
2006-02-15 |
2007-08-23 |
Matrix Laboratories Ltd |
An improved process for the preparation of candesartan cilexetil
|
CN101024643A
(zh)
|
2006-02-20 |
2007-08-29 |
上海艾力斯医药科技有限公司 |
咪唑-5-羧酸类衍生物、制备方法及其应用
|
WO2008035360A2
(en)
*
|
2006-06-13 |
2008-03-27 |
Alembic Limited |
Novel crystalline forms of candesartan cilexetil, candesartan, tritylated candesartan and tritylated candesartan cilexetil
|
WO2008012371A1
(en)
*
|
2006-07-28 |
2008-01-31 |
Krka, Tovarna Zdravil, D.D., Novo Mesto |
Process for the preparation of amorphous and crystalline forms of candesartan cilexetil using column chromatography
|
GEP20125420B
(en)
|
2006-08-10 |
2012-03-26 |
Takeda Pharmaceutical |
Solid pharmaceutical composition comprising benzimidazole compound
|
GB2444593B
(en)
|
2006-10-05 |
2010-06-09 |
Santarus Inc |
Novel formulations for immediate release of proton pump inhibitors and methods of using these formulations
|
EP1908469A1
(en)
|
2006-10-06 |
2008-04-09 |
Boehringer Ingelheim Vetmedica Gmbh |
Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
|
US8143435B2
(en)
*
|
2006-10-10 |
2012-03-27 |
Mylan Laboratories Ltd. |
One pot process for the preparation of candesartan
|
MX2009004475A
(es)
|
2006-10-27 |
2009-08-12 |
Univ Missouri |
Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
|
ES2315141B1
(es)
*
|
2006-11-23 |
2009-12-22 |
Quimica Sintetica, S.A |
Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina.
|
US8404896B2
(en)
|
2006-12-01 |
2013-03-26 |
Bristol-Myers Squibb Company |
N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
|
WO2008067687A1
(fr)
|
2006-12-06 |
2008-06-12 |
Shanghai Allist Pharmaceutical., Inc. |
Sels de dérivés d'acide imidazol-5-carboxylique, procédés de préparation et utilisation
|
CN101214242A
(zh)
|
2007-01-05 |
2008-07-09 |
上海艾力斯医药科技有限公司 |
新的药用组合物
|
EP1952806A1
(en)
|
2007-02-01 |
2008-08-06 |
Helm AG |
Process for the preparation of adsorbates of candesartan
|
TW200838501A
(en)
*
|
2007-02-02 |
2008-10-01 |
Theravance Inc |
Dual-acting antihypertensive agents
|
CA2677661A1
(en)
|
2007-02-07 |
2008-08-14 |
Kyowa Hakko Kirin Co., Ltd. |
Tricyclic compounds
|
US20080194307A1
(en)
*
|
2007-02-13 |
2008-08-14 |
Jeff Sanger |
Sports-based game of chance
|
KR20090115951A
(ko)
|
2007-03-01 |
2009-11-10 |
프로비오드룩 아게 |
글루타미닐 사이클라제 저해제의 신규 용도
|
CA2680449A1
(en)
*
|
2007-03-08 |
2008-09-12 |
Teva Pharmaceutical Industries Ltd. |
Pharmaceutical composition comprising candesartan cilexetil
|
NZ579851A
(en)
*
|
2007-03-28 |
2012-02-24 |
Takeda Pharmaceutical |
Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a ph control agent
|
US9656991B2
(en)
|
2007-04-18 |
2017-05-23 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
TWI448284B
(zh)
*
|
2007-04-24 |
2014-08-11 |
Theravance Inc |
雙效抗高血壓劑
|
SI22488A
(sl)
*
|
2007-04-24 |
2008-10-31 |
Krka, Tovarna Zdravil, D.D., Novo Mesto |
Kristalni 1-(cikloheksiloksikarboniloksi)etil 1-((2'-cianobifenil-4-il)metil) - 2-etoksi-1h-benz(d)imidazol -7-karboksilat in proces za njegovo pripravo
|
WO2008134013A2
(en)
|
2007-04-25 |
2008-11-06 |
Teva Pharmaceutical Industries Ltd. |
Pharmaceutical excipient complex
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
ES2393885T7
(es)
|
2007-06-04 |
2014-01-30 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
TWI406850B
(zh)
|
2007-06-05 |
2013-09-01 |
Theravance Inc |
雙效苯并咪唑抗高血壓劑
|
US20100210852A1
(en)
*
|
2007-07-11 |
2010-08-19 |
Alembic Limited |
Process for the preparation of candesartan cilexetil
|
WO2009035543A1
(en)
|
2007-09-07 |
2009-03-19 |
Theravance, Inc. |
Dual-acting antihypertensive agents
|
WO2009076288A1
(en)
|
2007-12-11 |
2009-06-18 |
Theravance, Inc. |
Dual-acting benzoimidazole derivative and their use as antihypertensive agents
|
CA2716367C
(en)
|
2008-02-20 |
2015-05-26 |
The Curators Of The University Of Missouri |
Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
|
US7989484B2
(en)
|
2008-04-29 |
2011-08-02 |
Theravance, Inc. |
Dual-acting antihypertensive agents
|
WO2009149279A2
(en)
|
2008-06-04 |
2009-12-10 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US20100210853A1
(en)
*
|
2008-06-24 |
2010-08-19 |
Hetero Research Foundation |
Process for preparation of candesartan cilexetil
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
US7863309B2
(en)
|
2008-07-24 |
2011-01-04 |
Theravance, Inc. |
Dual-acting antihypertensive agents
|
CN101648918B
(zh)
*
|
2008-08-15 |
2013-01-09 |
联化科技股份有限公司 |
坎地沙坦酯的中间体化合物及其合成方法
|
DK2165702T3
(da)
|
2008-09-17 |
2012-03-05 |
Helm Ag |
Stabile og let opløselige sammensætninger af candesartancilexetil fremstillet ved vådgranulering
|
US20100093701A1
(en)
*
|
2008-10-10 |
2010-04-15 |
Bruce Damiano |
Combination therapy comprising angiotensin receptor blockers and vasopressin receptor antagonists
|
KR100995755B1
(ko)
|
2008-10-31 |
2010-11-19 |
일동제약주식회사 |
트리틸 칸데사르탄 실렉세틸의 개선된 제조방법
|
DE102008059206A1
(de)
|
2008-11-27 |
2010-06-10 |
Bayer Schering Pharma Aktiengesellschaft |
Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
|
US9387249B2
(en)
|
2008-12-23 |
2016-07-12 |
Takeda Pharmaceutical Company Limited |
Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
|
WO2010093601A1
(en)
|
2009-02-10 |
2010-08-19 |
Metabasis Therapeutics, Inc. |
Novel sulfonic acid-containing thyromimetics, and methods for their use
|
JP5833000B2
(ja)
|
2009-07-07 |
2015-12-16 |
セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー |
二重に作用するピラゾール抗高血圧症薬
|
US8372984B2
(en)
|
2009-07-22 |
2013-02-12 |
Theravance, Inc. |
Dual-acting oxazole antihypertensive agents
|
JP5934645B2
(ja)
|
2009-09-11 |
2016-06-15 |
プロビオドルグ エージー |
グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
|
WO2011080684A1
(en)
|
2009-12-31 |
2011-07-07 |
Ranbaxy Laboratories Limited |
Process for the preparation of candesartan cilexetil
|
JP2013517295A
(ja)
|
2010-01-19 |
2013-05-16 |
セラヴァンス, インコーポレーテッド |
二重に作用するチオフェン、ピロール、チアゾールおよびフラン抗高血圧症薬
|
WO2011092666A1
(en)
|
2010-01-29 |
2011-08-04 |
Ranbaxy Laboratories Limited |
An improved process for the preparation of candesartan cilexetil, polymorphic forms of n-trityl candesartan and their uses thereof
|
JP6026284B2
(ja)
|
2010-03-03 |
2016-11-16 |
プロビオドルグ エージー |
グルタミニルシクラーゼの阻害剤
|
EP2545047B9
(en)
|
2010-03-10 |
2015-06-10 |
Probiodrug AG |
Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
|
EP2560953B1
(en)
|
2010-04-21 |
2016-01-06 |
Probiodrug AG |
Inhibitors of glutaminyl cyclase
|
CN101880241B
(zh)
*
|
2010-07-14 |
2013-04-17 |
浙江美诺华药物化学有限公司 |
一锅法制备2-(取代苯基)甲氨基-3-硝基苯甲酸甲酯的方法
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
KR101251741B1
(ko)
*
|
2010-12-16 |
2013-04-05 |
동화약품주식회사 |
칸데사르탄실렉세틸의 개선된 제조방법
|
US8530670B2
(en)
|
2011-03-16 |
2013-09-10 |
Probiodrug Ag |
Inhibitors
|
CN102198129B
(zh)
*
|
2011-03-22 |
2016-03-30 |
浙江华海药业股份有限公司 |
含有坎地沙坦酯和氢氯噻嗪的口服片剂
|
CN102206186A
(zh)
*
|
2011-04-18 |
2011-10-05 |
张家港市信谊化工有限公司 |
坎地沙坦环合物的制备方法
|
JP5898770B2
(ja)
|
2011-08-26 |
2016-04-06 |
ウォックハート リミテッド |
心血管疾患の治療方法
|
WO2013041944A1
(en)
|
2011-09-19 |
2013-03-28 |
Ranbaxy Laboratories Limited |
Process for the preparation of micronized candesartan cilexetil
|
JP5850697B2
(ja)
*
|
2011-10-18 |
2016-02-03 |
株式会社トクヤマ |
カンデサルタンシレキセチルの製造方法
|
BR112014014527A2
(pt)
|
2011-12-15 |
2017-06-13 |
Takeda Pharmaceuticals Usa Inc |
combinações de azilsartan e clorotalidona para tratar hipertensão em pacientes negros
|
CN102391254B
(zh)
*
|
2011-12-16 |
2013-03-13 |
珠海润都制药股份有限公司 |
一种坎地沙坦的制备方法
|
CN103304543A
(zh)
*
|
2012-03-12 |
2013-09-18 |
邓俐丽 |
一种坎地沙坦酯的制备方法
|
CN102633816A
(zh)
*
|
2012-03-30 |
2012-08-15 |
李莎 |
头孢西丁酯化前体药物化合物及口服制剂
|
ES2656292T3
(es)
|
2012-05-01 |
2018-02-26 |
Translatum Medicus Inc. |
Métodos de tratamiento y diagnóstico de enfermedades oculares que causan ceguera
|
CA2872542A1
(en)
|
2012-05-07 |
2013-11-14 |
Bayer Pharma Aktiengesellschaft |
Process for manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil
|
US20140134187A1
(en)
|
2012-06-25 |
2014-05-15 |
The Johns Hopkins University |
Therapeutic and diagnostic methods for autism spectrum disorders and other conditions
|
US9486503B2
(en)
|
2012-10-04 |
2016-11-08 |
Shionogi & Co., Ltd. |
Medicinal agent for suppressing malignant tumor metastasis
|
CN102952040A
(zh)
*
|
2012-11-20 |
2013-03-06 |
峨眉山天梁星制药有限公司 |
一种坎地沙坦酯中间体的硝基还原为氨基的方法
|
PL236001B1
(pl)
|
2012-12-21 |
2020-11-30 |
Adamed Spolka Z Ograniczona Odpowiedzialnoscia |
Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
|
WO2014151200A2
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
WO2014151206A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
US9339542B2
(en)
*
|
2013-04-16 |
2016-05-17 |
John L Couvaras |
Hypertension reducing composition
|
CA2909442A1
(en)
|
2013-04-17 |
2014-10-23 |
Pfizer Inc. |
N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
|
RS65632B1
(sr)
|
2013-06-05 |
2024-07-31 |
Bausch Health Ireland Ltd |
Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
|
ES2847904T3
(es)
|
2013-07-23 |
2021-08-04 |
Daiichi Sankyo Co Ltd |
Medicamento para la prevención o el tratamiento de la hipertensión
|
CN104098550A
(zh)
*
|
2014-07-17 |
2014-10-15 |
浙江华海药业股份有限公司 |
一种精制三苯甲基坎地沙坦的方法
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
US20180155326A1
(en)
*
|
2015-06-05 |
2018-06-07 |
Zhejiang Huahai Pharmaceutical Co., Ltd. |
Method for preparing trityl candesartan
|
CZ2015687A3
(cs)
|
2015-10-02 |
2017-04-12 |
Zentiva, K.S. |
Farmaceutická kompozice obsahující kombinaci kandesartanu, amlodipinu a hydrochlorthiazidu
|
EP3219309A1
(en)
|
2016-03-17 |
2017-09-20 |
K.H.S. Pharma Holding GmbH |
Fixed dosed pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension
|
KR20180123021A
(ko)
|
2016-03-24 |
2018-11-14 |
다이이찌 산쿄 가부시키가이샤 |
신질환의 치료를 위한 의약
|
CN106432201B
(zh)
*
|
2016-09-14 |
2019-04-23 |
威海迪素制药有限公司 |
一种坎地沙坦酯结晶的制备方法
|
KR20200026975A
(ko)
|
2017-07-07 |
2020-03-11 |
베링거잉겔하임베트메디카게엠베하 |
고양이에서 전신 질환의 예방 또는 치료를 위한 안지오텐신 ii 수용체 길항제
|
DK3461819T3
(da)
|
2017-09-29 |
2020-08-10 |
Probiodrug Ag |
Inhibitorer af glutaminylcyklase
|
WO2019200181A1
(en)
|
2018-04-11 |
2019-10-17 |
Ohio State Innovation Foundation |
Methods and compositions for sustained release microparticles for ocular drug delivery
|
WO2020140193A1
(zh)
|
2019-01-02 |
2020-07-09 |
临海市华南化工有限公司 |
一种坎地沙坦酯中间体的合成方法
|
MA54261A
(fr)
|
2019-01-18 |
2022-04-27 |
Astrazeneca Ab |
Inhibiteurs de pcsk9 et leurs procédés d'utilisation
|
CN110514758A
(zh)
*
|
2019-08-21 |
2019-11-29 |
天地恒一制药股份有限公司 |
一种坎地沙坦酯有关物质的检测方法
|
EP3984989A4
(en)
*
|
2020-08-13 |
2023-11-22 |
Nanjing Heron Pharmaceutical Science and Technology Co., Ltd. |
IBUPROFENESTER PRODRUG, PHARMACEUTICAL COMPOSITION AND PRODUCTION METHOD AND USE
|
US11655220B2
(en)
|
2020-10-22 |
2023-05-23 |
Hetero Labs Limited |
Process for the preparation of angiotensin II receptor blockers
|
EP4052695A1
(en)
|
2021-03-05 |
2022-09-07 |
Midas Pharma GmbH |
Stable oral fixed-dose immediate release pharmaceutical compositions comprising amlodipine, atorvastatin and candesartan cilexetil
|
EP4370101A1
(en)
|
2021-07-15 |
2024-05-22 |
Adamed Pharma S.A. |
A pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension
|
CN114149414B
(zh)
*
|
2021-12-23 |
2023-08-04 |
浙江永宁药业股份有限公司 |
一种利用微反应器连续流制备坎地沙坦的方法
|
WO2024075017A1
(en)
|
2022-10-04 |
2024-04-11 |
Zabirnyk Arsenii |
Inhibition of aortic valve calcification
|
EP4374855A1
(en)
|
2022-11-22 |
2024-05-29 |
KRKA, D.D., Novo Mesto |
Pharmaceutical dosage form of candesartan and indapamide
|